Phase IIb, 12-week, five-arm, global, double-blind, placebo-controlled study of modified-release dipyridamole/prednisolone in patients with moderate to severe rheumatoid arthritis: SYNERGY.

Trial Profile

Phase IIb, 12-week, five-arm, global, double-blind, placebo-controlled study of modified-release dipyridamole/prednisolone in patients with moderate to severe rheumatoid arthritis: SYNERGY.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2014

At a glance

  • Drugs Dipyridamole/prednisolone (Primary) ; Dipyridamole; Prednisolone; Prednisone
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SYNERGY
  • Sponsors Zalicus
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Sep 2012 Primary endpoint 'significant difference between dipyridamole and placebo in disease-activity-score' has been met, according to a Zalicus media release.
    • 13 Sep 2012 Secondary endpoint `significant difference between dipyridamole/prednisolone and prednisolone in disease activity score' not met, according to a Zalicus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top